[Unusual side effects in patients with psoriatic erythroderma treated with etretinate (RO 10-9359)].
The results of the treatment of psoriatic erythroderma are variable in different references. The authors describe the treatment of three patients and emphasize the immuno-modulatory action of etretinate on polymorphonuclears, monocytes and Langerhans cells and the possibility of an action on prostaglandins.
D000328:Adult; D000505:Alopecia / Q000139:chemically induced; D003873:Dermatitis, Exfoliative / Q000150:complications / Q000188:drug therapy*; D003875:Drug Eruptions / Q000097:blood / Q000209:etiology* / Q000276:immunology; D005050:Etretinate / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009260:Nail Diseases / Q000139:chemically induced; D011565:Psoriasis / Q000150:complications / Q000188:drug therapy* / Q000276:immunology
D005050:Etretinate
Efectos secundarios inhabituales en enfermos con eritrodermia psoriásica tratados con etretinato (RO 10-9359).